Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268319 · ClinicalTrials.gov registry record · NA
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
A NA study, sponsored by Infraredx.
- Terminated
- Registry status
- NA
- Development phase
- 85
- Enrollment target
NCT01268319: Clinical Trial NA study, sponsored by Infraredx.
NCT01268319 is a NA study that was terminated before completion, run by Infraredx. The registered enrollment target is 85 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01268319, a NA study, was terminated before completion, sponsored by Infraredx.
- TERMINATED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
Study Summary
The CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) Study is a pivotal trial to evaluate criteria for defining a Lipid Core Plaque (LCP) that is at high risk of rupturing during standard of care therapy and causing intra-procedural complications. If plaques that require treatment are at higher than normal risk of causing intra-procedural complications, some life threatening, the treating physician is better informed and may opt to take precautionary measures to mitigate the risk or result of a complication. The CANARY Study is also designed to evaluate the feasibility of using a distal embolization protection device (EPD) as a means to prevent heart attacks triggered by the embolization of plaque during standard care therapy. It is thought that the EPD will prevent plaque from going downstream during treatment and obstructing other heart vessels. These obstructions could cause heart attacks by preventing blood from reaching heart muscle tissue.
Primary Outcome
The occurrence of a peri-procedural MI in the context of the CANARY trial will be defined as an elevation of troponin I (cTnI), or troponin T (cTnT) above three times the upper limit of normal (\>3xULN).
Interventions
- DEVICE Embolic Protection Device (EPD)
- DEVICE Intracoronary Spectroscopy and Ultrasonic Evaluation
- DEVICE Angioplasty and Stent Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-11 |
| Phase | NA |
Why NCT01268319 stopped before completion
NCT01268319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Embolic Protection Device (EPD) is the first listed.
NCT01268319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01268319 about?
NCT01268319 is a clinical study titled "CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow". The CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) Study is a pivotal trial to evaluate criteria for defining a Lipid Core Plaque (LCP) that is at high risk of rupturing during standard of care therapy and causing intra-procedural complications. If plaques that...
What is the current status of trial NCT01268319?
This trial is currently terminated. It is a NA study. The enrollment target is 85 participants. The study started on 2011-05. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01268319?
The interventions under investigation include: Embolic Protection Device (EPD) (DEVICE), Intracoronary Spectroscopy and Ultrasonic Evaluation (DEVICE), Angioplasty and Stent Implant (DEVICE).
Who is sponsoring clinical trial NCT01268319?
This trial is sponsored by Infraredx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01268319's enrollment target sits among peer trials
85 980th of 2000 higher than 1,018 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia